CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 252 enrolled
Drug / intervention
Palbociclib +1 moredrug
Likely dose
Palbociclib 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02679755
NCT02679755Phase 4Completed
CompareCT.gov

A STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE

Pfizer·interventional·Posted Feb 10, 2016·Updated Jul 27, 2022

In Brief

A Phase 4 clinical trial evaluating Palbociclib and Letrozole for Breast Cancer. Completed, enrolled 252 participants across 34 sites in 2 countries.

Detailed Summary

A study of palbociclib in combination with letrozole as treatment of post-menopausal women with hormone receptor-positive, her2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesAustralia, India
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 10, 2016
Enrollment StartMar 9, 2016
Primary CompletionJul 25, 2019
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.4 years ago

Interventions

Palbociclibdrug

125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles

Letrozoledrug

2.5 mg/d tablets orally on a continuous regimen